Dividend Derby: AbbVie Vs. Pfizer Motley Fool Biogen reported solid phase 2b data last spring for daclizumab, and AbbVie and Bristol-Myers reported solid mid stage results for elotuzumab in previously treated myeloma patients last summer. Fool-worthy final thoughts. The ability to increase sales ... |
